Kenneth J. Dow
Compliance Officer chez CENTURY THERAPEUTICS, INC.
Profil
Kenneth J.
Dow is currently the Head-Legal & Compliance at Century Therapeutics, Inc. He previously worked as Vice President-Patent Law at Janssen Biotech, Inc., Vice President-Pharmaceutical Patent Strategy at Johnson & Johnson Law Department Europe, and Vice President-Law at Century Therapeutics, Inc. He has a graduate degree from St. John's University and an undergraduate degree from State University of New York at Buffalo.
Postes actifs de Kenneth J. Dow
| Sociétés | Poste | Début |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Compliance Officer | - |
Anciens postes connus de Kenneth J. Dow
| Sociétés | Poste | Fin |
|---|---|---|
Janssen Biotech, Inc.
 Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA. | Corporate Officer/Principal | - |
Johnson & Johnson Law Department Europe
 Johnson & Johnson Law Department Europe Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Johnson & Johnson Law Department Europe provides legal services. The private company is based in Buckinghamshire, UK. | Corporate Officer/Principal | - |
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | General Counsel | - |
Formation de Kenneth J. Dow
| St. John's University | Graduate Degree |
| State University of New York at Buffalo | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Janssen Biotech, Inc.
Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA. | Health Technology |
Johnson & Johnson Law Department Europe
Johnson & Johnson Law Department Europe Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Johnson & Johnson Law Department Europe provides legal services. The private company is based in Buckinghamshire, UK. | Commercial Services |
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
